Symptomatic Rebound Hypercalcemia After Denosumab Discontinuation in a Pediatric Patient With Cherubism

Background: Pediatric bone diseases due to osteoclast overactivity have limited therapeutic options. Denosumab, a human monoclonal antibody against RANK-ligand, has been used in the treatment of these conditions despite limited pediatric safety data. Rebound hypercalcemia after denosumab cessation i...

Descripción completa

Detalles Bibliográficos
Autores principales: Marpuri, Ian, Cheung, Clement C, Moke, Diana J, Ryabets-Lienhard, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089891/
http://dx.doi.org/10.1210/jendso/bvab048.1439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089891/
http://dx.doi.org/10.1210/jendso/bvab048.1439

Ejemplares similares